Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Arch Toxicol, 2018, 92(4):1435-1451. Pazopanib purchased from Selleck.

    (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

  • J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

    Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell M3fLdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvGR5VYUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;Mj64PYUuODVizszN MXLTRW5ITVJ?
human AN3-CA cell NFPYeZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlA2KG6P MUjTRW5ITVJ?
human CGTH-W-1 cell NU[1c|FVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml3mTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQxNjBzIH7N NVHYdYt3W0GQR1XS
human GDM-1 cell M4C0eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HSNmlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFMvQTlibl2= MYjTRW5ITVJ?
human A204 cell M4TqWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETQOVVKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFkvODZibl2= M3XPTHNCVkeHUh?=
human G-402 cell NHLaZ2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOxMlg1KG6P MWPTRW5ITVJ?
human MFE-296 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3qTnFVUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlk3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53OUCyNkDPxE1? MlnUV2FPT0WU
human NOS-1 cell NInHSFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PyWGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhcWN3ME2wMlY2QTh5IN88US=> M2\zenNCVkeHUh?=
human KG-1 cell NIj4doNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGtINTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkexO|U2KM7:TR?= M1v0T3NCVkeHUh?=
human HT55 cell NX7hSXN4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGhVPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4O|gyKM7:TR?= MWXTRW5ITVJ?
human MG-63 cell NYnGXpRlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4TXdWlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> NHK2eoVUSU6JRWK=
human CCF-STTG1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3uTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTFwMES5PFEh|ryP NWTCPHFmW0GQR1XS
human RT-112 cell MkToS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlO5TY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlExOzd4IN88US=> NWD2SZAxW0GQR1XS
human MC-IXC cell NXvqT4FIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13RVmlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yOTVzMjFOwG0> NIDyfFRUSU6JRWK=
human HUTU-80 cell NWjUZpZYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGWzRlNKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ6MUCzJO69VQ>? NX7UZVB1W0GQR1XS
human MV-4-11 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1PTBzIN88US=> MWHTRW5ITVJ?
human LCLC-103H cell M3vtNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUfTPI5IUW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVExO0hiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NYPiS2pMW0GQR1XS
human G-401 cell M2PZRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;ZSJJKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> NHXN[GFUSU6JRWK=
human A704 cell MljpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlX4TY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFMzOyEQvF2= NYfmSJhXW0GQR1XS
human ESS-1 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\VbGlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxOzl4IN88US=> NWrqd3Z6W0GQR1XS
human HLE cell M2LGSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVXUSHBRUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY{QDB2IN88US=> Mkn2V2FPT0WU
human NY cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\UPFBpUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPFQ5OjFizszN M3Xu[HNCVkeHUh?=
human A427 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm4NFc2KM7:TR?= MnfMV2FPT0WU
human SK-N-DZ cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1LlTmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODJ|OEGg{txO NY[3[Ww6W0GQR1XS
human J82 cell NVPpeJljT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGo5OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwME[wPFgh|ryP NH\QdIFUSU6JRWK=
human GI-1 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2T2OmlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN M4\ybnNCVkeHUh?=
human NCI-H716 cell M{\tU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzjdppKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? NVW1e4dTW0GQR1XS
human SF126 cell MnrnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj60O|Q2QSEQvF2= MlLyV2FPT0WU
human H4 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\FNoxKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61NVI3OiEQvF2= NV7EOGlmW0GQR1XS
human LB831-BLC cell NHf2SXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonxTY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? NFvpS5JUSU6JRWK=
human HCC1395 cell NFKyZlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUX0VZhVUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? M1L6VHNCVkeHUh?=
human LK-2 cell NVLXN2pJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1nSbWlvcGmkaYTpc44hd2ZiaIXtZY4hVEtvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlQ2PjlizszN MV;TRW5ITVJ?
human G-361 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HOWmlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA1ODh{IN88US=> NF72[FVUSU6JRWK=
human NCI-H2342 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPQOXlCUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1|LkGzN|E3KM7:TR?= MUTTRW5ITVJ?
human SK-LU-1 cell  Mn\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE5PzZ5IN88US=> MVjTRW5ITVJ?
human IGROV-1 cell  MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjWTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDdzMzFOwG0> NXfyfWQ4W0GQR1XS
human EB2 cell MmPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP NXe2NmE6W0GQR1XS
human CAL-54 cell M3jNZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVHzTYJLUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ6M{[3JO69VQ>? MmLCV2FPT0WU
human LB1047-RCC cell NU[yT3NQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnf3TY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> M1T1VXNCVkeHUh?=
Daudi cell NEDIdIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\jdWJbUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61N|E3PCEQvF2= M2nHNnNCVkeHUh?=
human Daudi cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUTRS2tbUW6qaXLpeIlwdiCxZjDoeY1idiCGYYXkbUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjZ{MUmg{txO Mo\hV2FPT0WU
human A172 cell NI\1RYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M375fGlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|M4QSEQvF2= NInNR21USU6JRWK=
human KGN cell NF;5e4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXLReoRMUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA3PzB7IN88US=> MlTsV2FPT0WU
human SNG-M cell NGXRUpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFG1T29KdmirYnn0bY9vKG:oIHj1cYFvKFOQRz3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDZ4OTFOwG0> NEL0XphUSU6JRWK=
human SW1710 cell M4\2Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFc{OThizszN NHzWUZBUSU6JRWK=
human HT29 cells NW[wUI5{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? M{jwV|E5PjJyM{iy
human A375P cells NGP5Z5hRem:uaX\ldoF1cW:wIHHzd4F6 Mn\ERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1VEBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= NFzDXXcyQDZ{MEO4Ni=>
human HN5 cells MnfTVJJwdGmoZYLheIlwdiCjc4PhfS=> NIfB[WJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= MV:xPFYzODN6Mh?=
HUVEC MlfLSpVv[3Srb36gZZN{[Xl? MkL0NUDPxE1? NI\D[283KGh? MYDBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? NVrUdIJ1OjRyM{[wOFI>
human Daoy cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke3PVQ6KM7:TR?= MkfTV2FPT0WU
human DMS-273 cell NFTvU|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk3OjB{IN88US=> NHfU[3NUSU6JRWK=
human KU812 cell Mn7NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6zO|gyOiEQvF2= MXzTRW5ITVJ?
human NCI-H727 cell NVe5TW5ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUfMeZVjUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEC5NFEh|ryP NETsPXlUSU6JRWK=
human P30-OHK cell MoLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN MUjTRW5ITVJ?
human MIA-PaCa-2 cell MoHMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{DOU2lvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkC0OlYh|ryP NWLqfVlVW0GQR1XS
human TT cell NXjPcohbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M33DbGlvcGmkaYTpc44hd2ZiaIXtZY4hXFRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2NlQh|ryP Mn7vV2FPT0WU
human DK-MG cell MlWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7rdVJKdmirYnn0bY9vKG:oIHj1cYFvKESNLV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB{ODFOoI0> M{L5SXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01072214 Completed Macular Degeneration GlaxoSmithKline March 9 2010 Phase 1
NCT00866528 Completed Lung Cancer Non-Small Cell GlaxoSmithKline July 9 2009 Phase 1
NCT02795819 Active not recruiting Renal Cell Carcinoma|Soft Tissue Sarcoma|Metastatic Disease Virginia Commonwealth University|National Cancer Institute (NCI) July 8 2016 Phase 1
NCT02450136 Recruiting Refractory Solid Tumors Samsung Medical Center October 8 2015 Not Applicable
NCT02300545 Recruiting Sarcoma Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8 2015 Phase 2
NCT01956669 Recruiting Solid Tumours Novartis Pharmaceuticals|Children''s Oncology Group|Novartis October 8 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID